Actelion Pharmaceuticals Ltd

act-064992d - macitentan/tadalafil

 

Study ID Status Type Title
AC-077-103 Completed Protocol Summary Single-center, open-label, single-dose, two-period, randomized, crossover, Phase I study to demonstrate bioequivalence between a fixed dose combination product formulation of macitentan/tadalafil (10 mg/40 mg) and the free combination of 10 mg macitentan (Opsumit®) and 40 mg tadalafil (Adcirca®) in healthy male and female subjects